| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$34.6M | ROE | −52.14% |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $169.3M | Trading Days | 1477 |
| 52W High | 6.91 |
| 52W Low | 1.00 |
| % Off High | −31.98% |
| YTD | 312.28% | 1Y | 339.25% |
| 3Y | −43.10% | 5Y | −43.98% |
| 10Y | −89.57% | Since incept. (ann.) | −20.14% |
| Ann. Volatility (1Y) | 132.44% | Ann. Volatility (3Y) | 110.05% |
| Sharpe (1Y) | 1.65 | Sharpe (3Y) | 0.46 |
| Max Drawdown (1Y) | −45.60% | Max Drawdown (3Y) | −95.45% |
| Beta (3Y, vs SPY) | −2.53 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | $168.3M | — |
| ORMP | ORAMED PHARMACEUTICALS INC. | $170.7M | 2.8 |
| LFCR | LIFECORE BIOMEDICAL, INC. \DE\ | $164.7M | — |
| HELP | CYBIN INC. | $164.2M | — |
| ARCT | Arcturus Therapeutics Holdings Inc. | $163.4M | — |
| CAMP | Camp4 Therapeutics Corp | $177.6M | — |
| KPTI | Karyopharm Therapeutics Inc. | $160.7M | — |
| OKUR | OnKure Therapeutics, Inc. | $159.6M | — |
| NKTX | Nkarta, Inc. | $158.8M | — |
| TNXP | Tonix Pharmaceuticals Holding Corp. | $158.5M | — |
| WHWK | Whitehawk Therapeutics, Inc. |
| $182.0M |
| — |
| PYXS | Pyxis Oncology, Inc. | $184.4M | — |
